Physician profile
Avery Barnhill
NPI 1861124240
$2,434.34
in general payments reported to CMS, 2019-2025
14 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $116 · 2024: $745 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $472.97 | 2024-2025 | Jot Dx, Aveir, Supera |
| Cvrx, INC. | $444.49 | 2025 | Barostim Neo System |
| Dexcom, INC. | $338.01 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| E.R. Squibb & Sons, L.L.C. | $252.96 | 2023-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $243.78 | 2024-2025 | Farxiga, Lokelma |
| Biomarin Pharmaceutical INC. | $133.93 | 2025 | Voxzogo 1.2mg |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $111.58 | 2024 | Gvoke Hypopen |
| Insulet Corporation | $104.03 | 2025 | Omnipod |
| Boston Scientific Corporation | $65.76 | 2025 | Cds - Mct/Cem Monitoring |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.24 | 2024-2025 | Jardiance |
| Bridgebio Pharma, INC. | $38.02 | 2025 | Attruby |
| Medtronic, INC. | $26.61 | 2025 | Symplicity G3 |
| Janssen Pharmaceuticals, INC | $22.96 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Barnhill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.